Crinetics Pharmaceuticals (CRNX) Projected to Post Earnings on Thursday

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings results after the market closes on Thursday, May 8th. Analysts expect Crinetics Pharmaceuticals to post earnings of ($0.99) per share and revenue of $0.10 million for the quarter.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. On average, analysts expect Crinetics Pharmaceuticals to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Crinetics Pharmaceuticals Trading Down 2.1 %

NASDAQ:CRNX traded down $0.72 during midday trading on Tuesday, hitting $32.93. 71,699 shares of the stock were exchanged, compared to its average volume of 858,186. The business has a 50-day moving average price of $32.19 and a two-hundred day moving average price of $43.10. The company has a market capitalization of $3.08 billion, a price-to-earnings ratio of -8.88 and a beta of 0.31. Crinetics Pharmaceuticals has a one year low of $24.10 and a one year high of $62.53.

Insider Activity at Crinetics Pharmaceuticals

In related news, CEO Richard Scott Struthers sold 17,338 shares of Crinetics Pharmaceuticals stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $34.20, for a total transaction of $592,959.60. Following the completion of the sale, the chief executive officer now owns 329,147 shares of the company's stock, valued at approximately $11,256,827.40. The trade was a 5.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Jeff E. Knight sold 7,162 shares of the stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $34.20, for a total value of $244,940.40. Following the transaction, the chief operating officer now owns 87,491 shares in the company, valued at approximately $2,992,192.20. This trade represents a 7.57 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,015 shares of company stock valued at $923,913. 6.00% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on CRNX shares. Stifel Nicolaus assumed coverage on shares of Crinetics Pharmaceuticals in a research report on Tuesday, March 25th. They set a "buy" rating and a $60.00 price objective on the stock. TD Cowen initiated coverage on Crinetics Pharmaceuticals in a report on Tuesday, February 11th. They set a "buy" rating on the stock. Wolfe Research initiated coverage on Crinetics Pharmaceuticals in a research note on Tuesday, February 4th. They issued a "peer perform" rating for the company. HC Wainwright reiterated a "buy" rating and issued a $81.00 target price on shares of Crinetics Pharmaceuticals in a report on Monday, January 13th. Finally, Jefferies Financial Group upgraded shares of Crinetics Pharmaceuticals from a "hold" rating to a "buy" rating and set a $55.00 price objective on the stock in a research note on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $73.00.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.